文献速递湿疹皮炎与荨麻疹

奈莫利珠单抗治疗特应性皮炎长达2年的开放标签扩展研究:安全性与疗效

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-10-13

ARCADIA长期扩展研究评估奈莫利珠单抗在≥12岁中重度特应性皮炎患者中长达200周的安全性与疗效,本次报告至第104周数据。1901例患者中1062例完成W104,多数不良事件为轻中度,仅22.1%被认为与药物相关;W104时IGA 0/1达58.2%-62.6%,EASI-75达85.4%-88.2%,瘙痒VAS改善≥4分达82.0%-87.2%。

要点

  • 持续奈莫利珠单抗治疗至W104耐受良好,多数不良事件为轻中度。
  • W104时约60%患者达到IGA 0/1,超过85%达到EASI-75。
  • W104时超过80%患者瘙痒VAS改善≥4分,约70%睡眠VAS改善≥4分。

核心结论

  • 持续奈莫利珠单抗治疗至第104周耐受良好,并在AD体征、症状及患者报告结局方面带来有临床意义的改善。

研究设计与样本

  • ARCADIA长期扩展研究纳入既往奈莫利珠单抗AD试验(2/3期)患者或新招募的中重度AD青少年,允许背景外用糖皮质激素和/或外用钙调神经磷酸酶抑制剂。
  • 长期安全性为主要终点,疗效为次要终点,本次报告截至第104周的观察数据,按LTE基线时既往有无奈莫利珠单抗暴露分为PNE和NNE。

主要发现

  • 数据截止2024年7月21日,1901例患者中1062例完成W104。
  • 92.6%的治疗中出现的不良事件(TEAE)为轻中度,仅22.1%被认为与奈莫利珠单抗相关。
  • 最常见(≥5.0%)TEAE为COVID-19(19.6%)、鼻咽炎(19.5%)、特应性皮炎(18.1%)、上呼吸道感染(12.7%)、头痛(6.5%)和哮喘(5.5%)。
  • LTE基线时PNE与NNE患者IGA 0/1分别为27.1%和17.1%,EASI-75分别为38.8%和25.8%,瘙痒VAS改善≥4分分别为58.7%和31.6%,睡眠VAS改善≥4分分别为52.9%和31.6%。
  • W104时PNE与NNE患者IGA 0/1分别为62.6%和58.2%,EASI-75分别为88.2%和85.4%,瘙痒VAS改善≥4分分别为87.2%和82.0%,睡眠VAS改善≥4分分别为70.8%和68.9%。

临床怎么用

  • 对于中重度特应性皮炎≥12岁患者,可考虑奈莫利珠单抗每4周皮下注射作为长期治疗选择,并联合外用药物控制病情。
  • 治疗期间应监测常见不良事件如感染、特应性皮炎加重、头痛和哮喘加重,多数为轻中度且未必与药物相关。

局限性

  • 本次报告为开放标签扩展研究截至第104周的观察数据,非对照设计。
  • 疗效数据为观察数据,未报告统计学比较或P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a common, chronic, relapsing, pruritic, neuroimmune skin disease, requiring long-term symptom control. OBJECTIVES: The ARCADIA long-term extension (LTE) study evaluates nemolizumab safety and efficacy in ≥12-year-old patients with moderate-to-severe AD up to 200 weeks. METHODS: Patients from previous nemolizumab AD trials (Phase 2/3) or newly recruited adolescents with moderate-to-severe AD were enrolled. A background regimen of topical corticosteroids with/without topical calcineurin inhibitors was permitted based on disease control. Long-term safety was the primary endpoint. Efficacy assessments were secondary endpoints, including the proportion of patients achieving Investigator's Global Assessment (IGA) 0/1 (clear/almost clear), Eczema Area and Severity Index (EASI)-75 (75% improvement from lead-in baseline in EASI), Visual Analogue Scale (VAS) Pruritus and VAS sleep loss ≥4-point improvement from lead-in baseline and quality of life. Observed data up to Week (W) 104 are presented for patients with previous nemolizumab experience (PNE) and no previous nemolizumab experience (NNE) at LTE baseline. RESULTS: At interim analysis data cut-off (21 July 2024), 1062 of 1901 patients completed W104. Exposure to nemolizumab in this study was equal across cohorts. The majority (92.6%) of treatment-emergent adverse events (TEAEs) were mild/moderate in severity; only 22.1% were considered related to nemolizumab. The most common (≥5.0%) TEAEs were COVID-19 (19.6%), nasopharyngitis (19.5%), atopic dermatitis (18.1%), upper respiratory tract infection (12.7%), headache (6.5%) and asthma (5.5%). At LTE baseline, the proportion of PNE and NNE patients was IGA 0/1: 27.1% and 17.1%; EASI-75: 38.8% and 25.8%; VAS Pruritus ≥4-point improvement: 58.7% and 31.6%; and VAS sleep loss ≥4-point improvement: 52.9% and 31.6%, respectively. At W104, this proportion was IGA 0/1: 62.6% and 58.2%; EASI-75: 88.2% and 85.4%; VAS Pruritus ≥4-point improvement: 87.2% and 82.0%; and VAS sleep loss ≥4-point improvement: 70.8% and 68.9%, respectively. CONCLUSIONS: Continuous nemolizumab treatment was well-tolerated through W104 with clinically meaningful improvements in AD signs and symptoms and patient-reported outcomes. TRIAL REGISTRATION: NCT03989206: https://clinicaltrials.gov/search?term=NCT03989206; EUDRACT number: 2019-001889-15. Data available upon request: clinical.studies@galderma.com. Atopic dermatitis, also known as eczema, is a common long‐lasting condition that causes itchy, inflamed and irritated skin. It often comes and goes and can have a big impact on well‐being with severe itch, skin pain, sleep deprivation, anxiety and depression. The world‐wide ARCADIA long‐term extension study followed 1901 patients with atopic dermatitis aged 12 years and older for up to 2 years to learn if nemolizumab, a medicine that stops itching and skin inflammation, was safe to use and improved atopic dermatitis and patient well‐being. Patients in the study received nemolizumab injections every 4 weeks, along with other skin creams or ointments. The study included patients who had never used nemolizumab before, and patients who had used nemolizumab in earlier studies. The researchers found that common adverse effects included cold‐like symptoms, worsening of atopic dermatitis, headaches and worsening of asthma. Most adverse effects were mild or moderate. 75% of adverse effects were unrelated to treatment with nemolizumab. After 2 years of treatment with nemolizumab, around 60% of patients had skin that was clear or almost clear of atopic dermatitis, and over 85% of patients had less severe atopic dermatitis. Over 80% of patients felt less itchy. Around 70% of patients slept better, and over 90% of patients said that atopic dermatitis had no or minimal impact on their well‐being. Nemolizumab appears to be a safe and effective long‐term treatment for atopic dermatitis. It can help clear the skin, reduce itching and improve sleep and well‐being.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Augustin M, Tauber M, Sidbury R, et al. Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study. J Eur Acad Dermatol Venereol. 2025. PMID: 41081535. doi:10.1111/jdv.70080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。